Trexall Articles
US FDA acts on cancer drugs shortages; move applauded by GPhA
22 February 2012
European Commission approves Bristol-Myers Squibb’s Orencia for combination use in pJIA
26 January 2010
Scotland’s SMC backs use of Roche’s Actemra, a drug still not allowed in England NHS
20 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Spectrum plunges on FDA letter delaying Fusilev approval in advanced metastatic colorectal cancer
12 October 2009
Japan stock market week to June 1, 2009
3 June 2009
Novartis buys generics cancer firm for $1.2B
20 May 2009
UCB gets FDA appro for Cimzia in RA
15 May 2009
FDA appro for J&J arthritis drug Simponi
28 April 2009
IDM gets EU appro for Mepact; seeking partner
23 March 2009
Rituxan slows joint damage in early RA
12 January 2009
FDA further delays Roche's Actemra over fears the drug may affect natal development and fertility
15 December 2008
Protherics cuts loss 23% over six months
1 December 2008
Cimzia plus MTX inhibits RA joint damage
1 December 2008
CHMP gives nod to four new drugs at meeting
1 December 2008
IDM gets EMEA nod, now looking to FDA
24 November 2008
Japan stock market week to Nov 3, 2008
10 November 2008
Strong data for Roche's Actemra in RA
3 November 2008
UCB presents data from two Ph III Cimzia trials
3 November 2008
Roche presents REFLEX study data for MabThera
3 November 2008
B-MS' Orencia almost doubles RA remission
3 November 2008
FDA asks for production info on Actemra BLA
29 September 2008
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
Introgen reports more Advexin data at AACR
4 August 2008
UCB's Cimzia under review for active RA
7 July 2008
Humira recommended for plaque psoriasis
30 June 2008
Roche's Actemra beats MTX in new RA studies
30 June 2008
Wyeth reports positive data from COMET trial
30 June 2008
Enbrel improves two measures of remission
23 June 2008
Orencia inhibits joint damage through three years
23 June 2008
GSK to test SC admin of cancer MAb
23 June 2008
RA golimumab patients see DAS28 remissions
23 June 2008
Advexin boosts survival in end-stage HN cancer
9 June 2008
Strong long-term psoriasis Raptiva data
19 May 2008
FDA approves B-MS' Orencia for JIA
14 April 2008
Japan stock market week to March 31, 2008
7 April 2008
58.5% of Actemra patients achieve ACR20
31 March 2008
Levoleucovorin gets US OK for osteosarcoma
17 March 2008
Cypress Biosci to buy Proprius for $75M
3 March 2008
Hollis-Eden's Triolex enters Ph I/II trial
18 February 2008
Patients on rituximab achieve ACR 20 response
4 February 2008
China acts on poor drug safety image
17 December 2007
Ph I/II US trial of tgACC94 resumes
3 December 2007
GSK/Genmab begin Ph III ofatumumab trials
3 December 2007
Roche files Actemra with FDA for RA
26 November 2007
New biologicals are the stars of the 2007 ACR meeting
19 November 2007
Strong long-term efficacy and safety data for Orencia
19 November 2007
BI's baminercept enters Ph IIb trials
19 November 2007
Cimzia plus MTX inhibits joint damage in RA
19 November 2007
Second drug suspension for China firm
10 September 2007
NICE accepts drugmaker case for RA drug
3 September 2007
US FDA accepts sBLA for B-MS' Orencia
13 August 2007
Roche's Actemra impresses in RA study
13 August 2007
Japan stock market week to July 16, 2007
23 July 2007
Roche's Actemra shows promise in RA trial
23 July 2007
China's SFDA recalls leukemia drug
16 July 2007
Rosehip reduces joint pain in RA patients
2 July 2007
Humira improves work performance in RA patients
25 June 2007
Roche's Actemra improves RA symptoms
25 June 2007
Protherics withdraws Voraxaze from EMEA
4 June 2007
EC clears B-MS' Orencia for RA
4 June 2007
SMC approves S-P's Remicade in psoriasis
21 May 2007
Abbott files Humira for childhood RA and IA
14 May 2007
B-MS' Orencia gets stronger US labeling
7 May 2007
Merrimack starts Ph II MM-093 enrollment
23 April 2007
Abbott seeks approval for Humira in psoriasis
9 April 2007
EC clears new Remicade dosing for use in RA
12 March 2007
Abbott's Humira effective as psoriasis therapy
12 February 2007
Japan stock market week to Jan 29, 2007
5 February 2007
Strong Ph III head-line data for Actemra
29 January 2007
Protherics updates on Voraxaze progress
15 January 2007
Atacicept to be examined in Ph II RA trial
22 December 2006
Strong Ph II data on S-P's golimumab
20 November 2006
B-MS reports two-year Orencia data in RA
20 November 2006
FDA delays Protherics' Voraxaze til 2008
13 November 2006
Humira superior to MTX in psoriasis study
16 October 2006
Protherics submits Voraxaze BLA to FDA
25 September 2006
Japan stock market week to July 31, 2006
7 August 2006
MabThera gets EU go-ahead for RA and NHL
17 July 2006
Enbrel and MTX therapy shows promise in RA trial
3 July 2006
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
